GREEN W/UV DC RED 295 BLT RED

WINNER RED ABS 650 UV TALL TIMBER SC UV BRIGHT WHITE SC

PE VIOLET SHEET UV 254C RED MM-34522 TPU ERMIME UV 18-1022

THERMO BLUE-RED UV YELLOW 130C PE UV TARGET CART RED

RED OVERMOLD BOOT UV MED. UV DECK WHITE PE 2

PP WHITE UV PP RED UV TRANS RED 201C PC

UV UNIVERSAL WHITE NY UV BLACK TANK PE RED CUP STY REPLACEMENT

RED MONOCONCENTRATE PMMA ELV RED GREY XENOY UV V2

GLs Th Derisn and manufa.luro ot Themopl 鏖锺燠 嬲 黜社璐黜 鑫嚣 山 Ⅱ 汹 ‘巾 ¨ 帧 Ⅱ 妒 舳 "0“ 岫 枷 啕 、 WⅡ ′ l黜嬲 獭 嫩 泛Oa ν 北 濒 ㈨ |● ,‘烹钔 △ 叻 “ ∞ ·Ⅱ ·酉雨 ● 莎 ●●幽 N"● `约 t艹 9△ ●o灬●矿 ●食⒋ 1 1∞ E) 0HsAs1 8001∶ oo ” ··Ⅱ "硫 ,kⅡ 0,ⅡⅡ官● Th$Ced lc仓怡 s Vεl|】0m24"ay 19 and remans rald suoJe4 oe6ld e θv |‘ r$σ ⒑∞ | ay2 邳 2 邳 2 ∞i ∞ 1θ o7 u‘ Ci^⒉ ●|m 0| Rec仓雨怆a】 on a刂 dl |$s刂ε‘ Ce雨Πe· Mu "忉 Ⅱ 9● 仓H sA Cssn∞ 2‘ s‘ sε‘ir st铜 ●芮 i∝柿 k蓟 铷 i∽ C◇ i9F0官 "● ″灿 "证 i0"●卸 N● 邪 ●●讧Ⅱm | 启●I●| PR 忄“ | i祁|"阳 翎 ,确 ‘ ∫“ |( ")‘ “⒊a12i、 ●息*W ●内 督 此 `Ⅱ 书 吉力士热塑混合材 oHsAs1 8001∶ J`囤 区吸菏 中国江讪 i ⒍0⒌⒉ 工 2 灼⒈ "市 核 ⒛彳⒐0冫19 亦 "llj″ 热塑性 ∶链体的设讠及和 该证l‘的有效丿”ti⒛ 丿颐 经过符个少水 彳90 2$ 效 行 I讪 0i, }泞眦H煳 2 o⒎o ⒉ I‘ "4I公 △‘j(讧 Ⅱ‘ ^灬 贩两 `￠ 灬 ●Ⅱ’、奥 Ⅱ‘‘ |Ⅱ ● "“ Ⅱu● ="∮ `Ⅱ ● △●Ⅱ‘ "40南 ∵1|● ‘、W 炉9彳 Ⅱ1△●礻i 品 讨 缃 社 锣 珊 号 γ 猢 扌 弟 !

Microsoft PowerPoint - Avient February IR Meetings AVIENT CORPORATION (NYSE: AVNT) F E B R U A R Y 1 7 - 1 8 , 2 0 2 1 I N V E S T O R M E E T I N G S H O S T E D B Y G O L D M A N S A C H S A N D M O R G A N S T A N L E Y DISCLAIMER Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 27 Avient reflects 2021 estimated EBITDA of $510M OUR VALUATION VERSUS PEERS Avient Specialty Other 9.5 21.1 13.2 13.2 12.0 12.0 9.7 25.2 23.1 14.7 13.5 12.9 11.0 11.0 11.0 10.2 9.6 9.3 9.3 9.1 8.6 8.3 Median: 11.0xMedian: 12.6x SUMMARY: WHY INVEST IN AVIENT? SEGMENT HIGHLIGHTS U.S. & Canada 50% 26% 16% Latin America 2020 SEGMENT, END MARKET AND GEOGRAPHY 30 GEOGRAPHY REVENUESEGMENT FINANCIALS 21%Industrial Building & Electrical & END MARKET REVENUE All data reflects 2020 Pro forma for acquisition of the Clariant Masterbatch business. (1) The total company sales and EBITDA of $3,783M and $457M, respectively, include intercompany sales eliminations and corporate costs $2,043M $331M $709M $124M $1,110M $70M Sales EBITDA Distribution Specialty Engineered Materials Color Additives and Inks $457M$3,783M 35% 14% Building & Electrical & C O L O R , A D D I T I V E S & I N K S 2020 PF REVENUE | $2 .0 BILLION 31% 40% 22% Latin America END MARKET REGION 31 2020 figures Pro forma for acquisition of the Clariant Masterbatch business S P E C I A LT Y E N G I N E E R E D M AT E R I A L S 24% Wire & Cable(1) 24% Electrical & 13% Transporation 11% Building & 2020 REVENUE | $709 MILLION END MARKET 58% 19% REGION 32 (1) Approximately 50% of Wire and Cable sales are associated with Fiber Optic Cabling DI S TR IBU T I ON 2020 REVENUE | $1 .1 B ILL ION 29% 25% 20% 14% Electrical & Building & 1% 82% Latin America END MARKET REGION K E Y S U P P L I ER S 33 AMERICAS EMEA ASIA 26% 19% 13% 16% Building & Electrical & 34% 16%Healthcare 17% Building & Electrical & 32% 27% 12% Building & Electrical & 9% 2020 figures Pro forma for acquisition of the Clariant Masterbatch business TOTA L C O M PA N Y R E G I O N A L S A L E S BY END MARKET (58% of sales) (26% of sales) (16% of sales) 34 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.